Virtu KCG Holdings LLC boosted its holdings in Moleculin Biotech, Inc. (NASDAQ:MBRX) by 54.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 361,351 shares of the company’s stock after purchasing an additional 127,357 shares during the period. Virtu KCG Holdings LLC owned about 2.04% of Moleculin Biotech worth $676,000 as of its most recent SEC filing.

Separately, Vanguard Group Inc. boosted its position in Moleculin Biotech by 27.7% in the second quarter. Vanguard Group Inc. now owns 337,321 shares of the company’s stock worth $631,000 after purchasing an additional 73,161 shares during the last quarter. 5.13% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at

Separately, ValuEngine raised Moleculin Biotech from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.

In other Moleculin Biotech news, major shareholder Waldemar Priebe sold 100,000 shares of Moleculin Biotech stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $1.70, for a total value of $170,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 20.80% of the stock is currently owned by company insiders.

Moleculin Biotech, Inc. (NASDAQ MBRX) opened at 2.46 on Friday. Moleculin Biotech, Inc. has a 52-week low of $0.71 and a 52-week high of $6.21. The stock’s market cap is $49.84 million. The firm has a 50-day moving average price of $2.52 and a 200 day moving average price of $1.45.

Moleculin Biotech (NASDAQ:MBRX) last posted its earnings results on Monday, August 14th. The company reported ($0.19) EPS for the quarter. On average, analysts forecast that Moleculin Biotech, Inc. will post ($0.34) earnings per share for the current fiscal year.

About Moleculin Biotech

Moleculin Biotech, Inc is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML).

Want to see what other hedge funds are holding MBRX? Visit to get the latest 13F filings and insider trades for Moleculin Biotech, Inc. (NASDAQ:MBRX).

Receive News & Ratings for Moleculin Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.